Debio 0123
Alternative Names: Debio-0123Latest Information Update: 14 Jul 2024
At a glance
- Originator Almac Discovery
- Developer Almac Discovery; Debiopharm; Repare Therapeutics
- Class Antineoplastics
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Glioblastoma
- Phase I Small cell lung cancer; Solid tumours
- No development reported Cancer
Most Recent Events
- 31 May 2024 Efficacy, adverse event and pharmacokinetics data from a phase I trial in Solid tumour presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 May 2024 Debiopharm in collaboration with MEDSIR plans a phase Ib/II trial in Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Europe, and United Kingdom (PO)
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)